EMVISION MEDICAL DEVICES LTD — Director's Dealing 2021

Dec 22, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity EMvision Medical Devices Ltd ABN 38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Geoff Pocock
Date of last notice	3 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	OOFY PROSSER PTY LTD FAMILY A/C> - Controller of trustee and beneficiary of trust
Date of change	22 December 2021
No. of securities held prior to change	OOFY PROSSER PTY LTD FAMILY A/C> 355,000 ordinary shares (EMV) 500,000 unlisted options, exercise price 35c, expiry date 31 Dec 2021
Class	Ordinary shares & options
Number acquired	500,000 ordinary shares
Number disposed	500,000 exercised options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$175,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	OOFY PROSSER PTY LTD FAMILY A/C> 855,000 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity EMvision Medical Devices Ltd ABN 38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Tony Keane
Date of last notice	13 December 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	PATRICIA KERRY KEANE & ANTHONY GERARD KEANE A/C> - Trustee and beneficiary of trust
Date of change	22 December 2021
No. of securities held prior to change	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV) PATRICIA KERRY KEANE & ANTHONY GERARD KEANE A/C> 500,000 unlisted options, exercise price 35c, expiry date 31 Dec 2021
Class	Ordinary shares & options
Number acquired	500,000 ordinary shares
Number disposed	500,000 exercised options

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$175,000
No. of securities held after change	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV) PATRICIA KERRY KEANE & ANTHONY GERARD KEANE A/C> 500,000 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity EMVision Medical Devices Ltd ABN 38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr John Keep
Date of last notice	13 December 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JOHN KEEP & SONS PTY LTD – Controller of company GLENSBURG PTY LTD CORPORATION PENSION FUND A/C> - Controller of trustee and beneficiary of trust
Date of change	22 December 2021
No. of securities held prior to change	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV) GLENSBURG PTY LTD CORPORATION PENSION FUND A/C> 1,100,000 ordinary shares (EMV) JOHN KEEP 400,000 unlisted options, exercise price 35c, expiry date 31 Dec 2021
Class	Ordinary shares & options

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	347,170 ordinary shares
Number disposed	347,170 exercised options 52,830 cancelled options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Employee share scheme option terms include a cashless exercise mechanism. 52,830 options have been cancelled equal to the value of the exercise proceeds due ($140,000) using the 15 day VWAP of $2.65 at notice of exercise.
No. of securities held after change	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV) GLENSBURG PTY LTD CORPORATION PENSION FUND A/C> 1,100,000 ordinary shares (EMV) JOHN KEEP 347,170 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity EMVision Medical Devices Ltd ABN 38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ronald Weinberger
Date of last notice	15 April 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Deborah Joan Weinberger (spouse)
Date of change	22 December 2021
No. of securities held prior to change	Dr Ronald Peter Weinberger: 1,017,200 fully paid ordinary shares 1,000,000 unlisted Series A options over ordinary shares, exercise price $0.35, expiry date 31 December 2021 1,000,000 unlisted Series F options over ordinary shares, exercise price $1.25, expiry date 6 May 2023 Deborah Joan Weinberger: 20,000 fully paid ordinary shares
Class	Ordinary shares & options

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	867,925 ordinary shares
Number disposed	867,925 exercised options 132,075 cancelled options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Employee share scheme option terms include a cashless exercise mechanism. 132,075 options have been cancelled equal to the value of the exercise proceeds due ($350,000) using the 15 day VWAP of $2.65 at notice of exercise.
No. of securities held after change	Dr Ronald Peter Weinberger: 1,885,125 fully paid ordinary shares 1,000,000 unlisted Series F options over ordinary shares, exercise price $1.25, expiry date 6 May 2023 Deborah Joan Weinberger: 20,000 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity EMvision Medical Devices Ltd ABN 38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Scott Kirkland
Date of last notice	21 December 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	KIRKLAND CAPITAL PTY LTD FURKHAND A/C> - Controller of Trustee and beneficiary of trust
Date of change	22 December 2021
No. of securities held prior to change	Mr Scott Philip Kirkland 3,333,400 ordinary shares (EMV) 600,000 unlisted options, exercise price 35c, expiry date 31 Dec 2021 KIRKLAND CAPITAL PTY LTD 415,000 total ordinary shares (EMV)
Class	Ordinary shares & options
Number acquired	520,755 ordinary shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	520,755 exercised options 79,245 cancelled options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Employee share scheme option terms include a cashless exercise mechanism. 79,245 options have been cancelled equal to the value of the exercise proceeds due ($210,000) using the 15 day VWAP of $2.65 at notice of exercise.
No. of securities held after change	Mr Scott Philip Kirkland 3,854,155 ordinary shares (EMV) KIRKLAND CAPITAL PTY LTD 415,000 total ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Exercise of options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3